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Abstract 
Introduction: Lansoprazole is one of the proton pump inhibitor drugs widely used in the 
treatment of gastro-duodenal ulcers and disorders. However, there is not enough data about 
unexplored adverse effects of lansoprazole on the integrity of the placental barrier. Therefore, 
the present study was conducted to determine whether placental structure could be affected 
by lansoprazole administration.  
Materials and methods: A total of 24 pregnant Balb/C mice were randomly divided into one 
control and three experiment groups (n=6).The experimental animals were given 25, 50 and 
100 mg/kg of lansoprazole intraperitoneally on days 6-16 of pregnancy. At the end point and 
on the day 17 of gestation all animals were sacrificed. Then, the placentas specimens were 
taken and processed for histological examinations. Histological sections were stained with 
hematoxylin-eosin and were examined under light microscopy. 
Results: The histological examinations showed remarkable cellular changes in the placenta 
after treatment with lansoprazole. The placentas from drug administrated mice exhibited 
conspicuous decrease in the spongy layers size when compared with controls. Also, both 
polymorph and mononuclear cell infiltration into placental parenchyma were seen in the 
animals treated with 100 mg/kg lansoprazole. In addition, dilation of the intervillous space, 
massive vasculature congestion, increased giant cell population and fibroblastic proliferation 
were seen in the placental tissues from experimental groups. 
Conclusion: The findings of the present study led us to investigate the effect of the 
lansoprazole administration on the mouse placenta. Taken together, this drug should not be 
prescribed during pregnancy. 
Keywords: Histology, Placenta, Mouse, Lansoprazole, Health 
Introduction 
Lansoprazole is one of the most proton 
pump inhibitor drugs (PPIs) that widely 
prescribed for the treatment of gastro-
duodenal ulcers and disorders. It acts as 
noncompetitive inhibitors of the H+/K+ 
ATPase enzyme in the parietal cell 
membrane of the stomach (1). In spite of 
most frequently prescription; lansoprazole 
has recently been suggested to induce 
some adverse effects in the laboratory 
animal studies. For example, the effects of 
PPIs administration on the lung, stomach 
and oro-pharyngeal microorganism 
contents have been criticized in the 
recently published studies (2). It has also 
been shown that taking 30 mg of 
lansoprazole could induce Kounis 
syndrome in a 52 year old man (3). 
Additionally, PPIs including lansoprazole 
may exert direct negative effects on the 
structure and function of the immune 
system (4). Furthermore, PPIs has been 
*Corresponding author: Tel: +98 8432224308 Fax: +98 8432224308 
Address: Department of Basic Science, Faculty of Para-Veterinary Medicine, University of Ilam, Ilam -Iran. 
Postal code: 69315-516 
E-mail: alm722@gmail.com 
Received; 2016/05/1 revised; 2016/06/30 accepted; 2016/08/17 
 
D
ow
nl
oa
de
d 
fro
m
 jb
rm
s.m
ed
ila
m.
ac
.ir 
at 
9:4
5 I
RS
T o
n T
ue
sd
ay
 D
ec
em
be
r 5
th 
20
17
    
    
  [ 
DO
I: 1
0.1
88
69
/ac
ad
pu
b.j
brm
s.4
.2.
24
 ]  
Original article                                                              J Bas Res Med Sci 2017; 4(2):24-28 . 
25 
 
considered as a potential causative agent 
for developing the acute interstitial 
nephritis (5) and as well as celiac disease 
(6). 
As above mentioned, there are many 
literature investigations on the potential 
complications of the PPI including 
lansoprazole on the various organs in the 
body. On the other hands, in spite of 
common occurrence of gastro intestinal 
disorders during pregnancy, there is not 
enough data about probable adverse effects 
of lansoprazole administration on the 
placenta as a major endocrine organ during 
pregnancy. Since many subjects need to 
take PPI medicines for treatment of the 
gastro-duodenal disorders during 
pregnancy, therefore; the present study 
was conducted to determine whether 
placental structure could be affected by 
lansoprazole administration. 
Materials and methods  
In this study, the experimental protocols 
were approved by the institutional animal 
care and use ethics committee of Ilam 
University . 
 For this study a total of 24 pregnant 
Balb/C mice were randomly divided into 
one control and three experiment groups 
(n=6). The experimental animals were 
given 25, 50 and 100 mg/kg of 
lansoprazole intraperitoneally (i.p.) on 
days 6-16 of pregnancy. The control group 
was treated by intraperitoneal injection of 
distilled water in the same manner to the 
experimental animals. All animals were 
fed standard laboratory chow and tap 
water ad libitum throughout the study.
  At the end point and on the day 17 
of gestation, all animals were sacrificed. 
Then, the placentas specimens were taken 
and processed for histological 
examinations. For histological study, the 
specimens were fixed in the formalin10%; 
then sectioned by microtome at 6 microns 
and mounted on the glassy slides. The 
prepared slides were stained with 
hematoxylin-eosin and examined under a 
light microscope. The proportion of 
various placental areas was compared 
between various groups.  
Results 
The histological studies of the placentas 
from control and experiments group are 
shown in the figures 1 and 2. The 
histological examinations showed 
remarkable cellular changes in the placenta 
after treatment with lansoprazole (Figure 
1). The placentas from drug administrated 
animals exhibited conspicuous decrease in 
the spongy layers size when compared 
with controls (Figure 1). 
 Also, both polymorph and mononuclear 
cell infiltration into placental parenchyma 
were seen in the animals treated with 100 
mg/kg lansoprazole (Figures 1 and 2). 
In addition, in the placental tissues from 
experimental groups; the intervillous 
spaces were more dilated (figure 1-d). 
Similarly, in the experimental groups the 
placental parenchyma was occupied with 
fibroblast cell proliferation than in the 
controls (Figure 2). Furthermore, in the 
experimental placental sections, the 
maternal and fetal blood vessels were 
relatively dilated and vessels massive 
vasculature congestion was remarkable 
(Figure 2). Finally, the number and the 
size of the trophoblastic giant cells were 
found to be increased in the treated 
animals (Figure 2). 
 Discussion 
Lansoprazole is an effective proton pump 
inhibitor drug act by irreversibly blocking 
the hydrogen/potassium adenosine 
triphosphatase enzyme system in the 
parietal cell membrane of the stomach. It 
is used for the treatment of gastro-
duodenal disorders and peptic ulcers 
especially during pregnancy (7). Since 
many subjects need to take lansoprazole 
medicines for treatment of the gastro-
duodenal disorders during pregnancy; the 
present study aims to investigate its 
probable adverse effects on the mouse’s 
placenta.
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Figure 1. Placental histology of the control group. The double head arrow indicates the normal size of the 
spongy layer (a). Placental histology of the treated animals with lansoprazole at 100 mg/kg. This figure reveals 
the conspicuous decrease in the spongy layers s size (b).  Placental histology of the control animals. The star 
represents the normal size of the inter-villous spaces(c). Placental histology of the treated animals with 
lansoprazole at 50 mg/kg. The arrow reveals the lymphoid cells infiltration in the placental parenchyma. As star 
reveals the intervillous spaces are more dilated (d). (Haematoxylin and Eosine) (Magnification: × 100 a, b. × 
400 c, d). 
 
 
 
Figure 2. Placental histology of the treated animals with lansoprazole at 100 mg/kg. As arrows indicate the 
placental parenchyma are occupied with fibroblast cell proliferation (a). Higher magnification of the marked 
area in the figure 2-a (b). Placental histology of the treated animals with lansoprazole at 50 mg/kg. The arrow 
indicates remarkable vessels congestion(c). Placental histology of the treated animals with lansoprazole at 50 
mg/kg. As arrow indicates the number and size of the trophoblastic giant cells are increased (d). (Haematoxylin 
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and Eosine) (Magnification: × 100 a, c. × 400 b, d). 
 
Overall, the present histological results 
clearly demonstrated that lansoprazole 
administration at organogenesis period of 
the mouse placenta could exert remarkable 
harmful impacts. On the basis of the 
reproductive investigation which have 
been done in the pregnant rats; 
lansoprazole at concentrations of 50 and 
300 mg/kg could cause a significant 
decrease in the fetal weight (8). Similarly, 
it has been suggested that higher incidence 
of birth defects and major congenital 
malformations were seen in the patient 
which exposed to lansoprazole before 
pregnancy (9). Because of placental 
dysfunction has been positively correlated 
with fetal weight retardation and can also 
restrict embryo growth by limiting nutrient 
exchange between mother and 
embryo(10), therefore, the above 
mentioned literatures are in keeping with 
the obtained data in the present research.  
Although it is not known whether the 
administered lansoprazole to the pregnant 
mothers have the potential to cross the 
placenta, but its molecular weight is low 
enough that passage across the placenta 
and reach embryo (11). So, the present 
results on the placental histology can 
indicate readily diffuse of lansoprazole 
across the placental membrane and reach 
the fetus . 
In the current work the polymorph and 
mononuclear lymphoid cells infiltration in 
the placental parenchyma after drug 
exposure is abnormal. Indeed, any 
elevation in the lymphoid cells infiltration 
seems to indicate the occurrence of 
inflammation in the placental tissue and 
related to experimental dosing. 
Present findings provided the first 
experimental evidence that lansoprazole 
induces noticeable detrimental impacts on 
the murine placenta. There are not any 
investigations in the literature about the 
effects of the lansoprazole on placenta 
which compared with present findings . 
In the current investigation the number and 
size of the trophoblastic giant cells were 
found to be increased after lansoprazole 
prescription. It has been demonstrated that 
trophoblastic giant cells are precursors of 
invasive trophoblasts that collaborates 
channels within the labyrinthine region of 
the murine placenta (12). Since feto-
maternal interface occurs within the 
labyrinthine zone (13), therefore, the 
trophoblastic giant cells impairments 
suggests these critical nutrient transport 
site were compromised by lansoprazole 
exposure. 
Although mechanism underlying placental 
toxicity in the case of lanzoprazole 
treatment is not clear; but it is likely 
multifactorial and maybe is due to this 
facts that trophoblastic cells might be 
vulnerable to the inhibition of proton 
extrusion and inhibition of the ATPase 
activity during drug exposure (14). In 
addition to this phenomenon, the immune-
modulatory effects of PPIs (4) including 
lanzoprazole could be a major risk factor 
for placental insufficiency. 
 Further work is needed to elucidate the 
possible association between lansoprazole 
exposure and placental tissue alterations.  
The limitation of the present study was the 
lack of electron microscopy research 
accompanying the histological alterations. 
Conclusion 
The findings of the present work led us to 
investigate the effect of the lansoprazole 
administration on the mouse placenta. 
Taken together, this drug should not be 
prescribed during pregnancy.
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